Our Pitch:The Inevitable $9T Longevity Megatrend/Economy/Economic Trend

The Inevitable Opportunity

By 2030, the global longevity and healthy aging economy will surpass $9 Trillion. Extending human healthspan to better match our longer lifespans is the single largest commercial opportunity of our generation.

Why Generalist VC Fails

Early-stage biotech, AI therapeutics, and frontier medtech cannot be properly evaluated by generalist funds. They lack the clinical lens required to accurately underwrite technical risk—meaning they routinely miss or misprice the next generation of healthcare unicorns.

The 1004VP Edge

1004 Venture Partners is a hyper-focused boutique firm built to win. We offer three distinct structural advantages:

• Scientific Authority: With decades of collective experience spanning biotech, life sciences, and medtech, our leadership team speaks the language of frontier science. Our deep academic and biotech startup roots allow us to validate breakthrough technologies long before the mainstream market even sees it.

• The Founder Magnet: Elite healthtech founders often reject passive, generalist capital. They actively choose 1004VP for our deep clinical mentorship, corporate syndicate networks, and hands-on company co-building.

• AI-Driven Velocity/Veracity: Powered by internal AI multi-agent orchestration, our structure eliminates administrative drag. We source deeper, diligence faster, and deploy capital with unmatched precision.